Join industry expert Dr. Jason Creasy from GlaxoSmithKline as he talks with The Medicine Maker magazine about the history, developments and future of extractable impurities testing for pharmaceuticals.
Extractables and Leachables Information
Identify and quantify leachable impurities
A drug product container-closure system should not release chemicals that can accumulate in the drug product in quantities sufficient to present a risk of toxicity, or affect its stability or efficacy.
We are unique in offering comprehensive analytical workflows including ICP-MS, GC-MS, LC-MS and advanced information to enable identification and quantification of unknown organic and elemental impurities.
Extractable and leachable impurities from pharmaceutical container-closure and production systems
In May 1999, the U.S. FDA published a guidance document on Container Closure Systems for Packaging Human Drugs and Biologics. The FDA mandated that pharmaceutical manufacturers demonstrate the safety of materials used in production systems, container closure systems or drug delivery devices. Failure to demonstrate material safety could result in failure to receive FDA approval for a product. Everything from glass and plastic bottles to foil pouches and the ink used in labels and packaging materials has the potential to leach unwanted contaminants into a drug product.
What are "extractables"?
In order to study the risk of materials extraction studies are performed; generally using aggressive solvent conditions including acidic, basic, organic and aqueous solvents and sohxlet or accelerated solvent extraction. It is important that the extraction process does not deform the material of interest. Compounds present in the resulting extracts are called "extractables". Extractables studies are typically performed to create a "worst case scenario" and assist in materials selection and early risk assessment.
What are "leachables"?
Leachables are chemical species that make their way into the product under normal product, application or storage conditions. There is generally an overlap such that the leachables involved may be classified as a subset of the extractables. Forced or accelerated leachable studies can be performed to assess leachables that migrate under simulated environmental conditions by analyzing the drug formulation after exposure to elevated temperature. However, if the leachable interacts with the drug product or packaging materials, new components can be present. These are termed secondary leachables. Drug formulations often contain buffers, surfactants, fillers and other excipients. This complexity means that there are sometimes secondary leachables that can only be identified after long stability studies over the typical drug shelf life.
Detecting extractables and leachables: using the right tests
Extractable and leachable studies identify key components using a range of analytical technologies:
- Volatile organic compounds —typically performed using headspace GC-MS
- Semi-volatile organic compounds —typically performed using GC-MS or high resolution accurate mass (HRAM) GC-MS
- Non-volatile organic compounds —typically performed HRAM LC-MS/MS
- Elemental impurities (metals) —typically performed ICP-MS
Quantification of these compounds is performed using relative reference standards, in which a qualified toxicologist calculates the analytical evaluation threshold (AET), above which an extractable or leachable needs to be reported for toxicological assessment. Analytical data for these impurity classes is meant to provide information to help customers determine what further studies are needed to mitigate risks associated with the final product.
There are currently no single regulated method prescribed for analyzing extractables and leachables. Generally, the Product Quality Research Institute (PQRI) recommendation document in the table below is accepted by the industry as a primary recommendation to follow as it was drafted with U.S. FDA involvement. However, to date it has not been formally accepted. There are several methods in draft currently being considered by global regulators and guidance documents from industry bodies, such as BioPhorum Operations Group (BPOG) and BioProcess Systems Alliance (BPSA):
|PQRI||OINDP Drugs||Best Practices for Extractables and Leachables in Orally Inhaled and Nasal Drug Products: An Overview of the PQRI Recommendations||2008|
|U.S. Pharmacopeia||Plastic Packaging||USP <661>: Plastic Packaging Systems and Their Materials of Construction||2016|
|BPOG||Bioprocess Materials||Standardized Extractables Testing Protocol for Single-Use Systems in Biomanufacturing||2014|
|BPSA||Bioprocess Materials||Recommendations for Testing and Evaluation of Extractables from Single-Use Process Equipment||2010|
|BPSA||Bioprocess Materials||Recommendations for Extractables and Leachables Testing||2008|
Featured extractables & leachables learning content
Join this 3-part webinar series to learn extractables and leachables testing for pharmaceutical container-closure systems and food contact materials. Hear from experts about regulations and the latest technologies and workflows to deliver E&L testing.
The National Institute for Bioprocessing Research and Training (NIBRT) is publishing new research investigating extractable & leachable impurities in the manufacture of biopharmaceuticals. Get their groundbreaking research report first.
Learn how the most advanced GC-MS technology available can be used to give absolute confidence in unknown identification and quantification of extractable and leachable impurities.
Join applications scientist Keeley Murphy as he presents this extractables and leachables poster at the American Association of Pharmaceutical Scientists (AAPS) conference.
In this study, comprehensive extractables analysis of USP class VI O-rings was conducted using LC-MS and ICP-MS. Organic compounds were identified using mzCloud high-resolution MS/MS libraries.